Immunotherapy Platform
Translating immuno-oncology discovery into clinical impact
Since 2012, the Immunotherapy Platform (IMT) has integrated genomics, spatial biology, pathology and data science to accelerate biomarker discovery and translational immuno-oncology research. Through close integration with clinical studies, IMT helps transform complex biomedical data into clinically actionable insights.
Scientific Pillars
Overview
The Immunotherapy Platform (IMT) is structured around three integrated scientific pillars that jointly enable translational immuno-oncology research.
Multi-Parametric Immune Monitoring
Led by Sreyashi Basu, Ph.D., the Multi-Parametric Immune Monitoring team conducts high-dimensional immune profiling across single-cell, bulk and spatial transcriptomic modalities, integrated with functional immune assays and data-driven analyses to define interpretable immune states, spatial architectures and predictive biomarkers associated with treatment response and resistance.
Spatial & Digital Pathology
Led by Sonali Jindal, M.D., the Spatial and Digital Pathology team drives clinical translation through a multi-modal pathology framework that leverages pathological review, immunohistochemistry and multiplex IF imaging to pair with transcriptomic insights for characterizing the spatial state of the tumor to define mechanisms of response and advance precision medicine.
Data Science
Led by Alejandro Jimenez Sanchez, Ph.D., the Data Science team develops computational and machine learning frameworks for multimodal integration, statistical and systems-level modeling, predictive biomarker discovery and scalable translational analytics across single-cell, spatial, clinical and high-dimensional molecular datasets.
Collaborate with IMT
We partner with academic investigators and industry collaborators to design and execute translational immuno-oncology studies.
For academic investigators
We provide study design consultation, translational profiling, and biomarker discovery support for clinical and preclinical immuno-oncology studies.
For industry / pharma
We support translational biomarker strategy, multi-modal profiling, clinical trial correlative science, and predictive modeling through collaborative partnerships.
Acknowledgment Guidelines
If IMT contributed to your study, please acknowledge the platform in resulting publications.
Suggested wording: “We acknowledge the Immunotherapy Platform (IMT) at the James P. Allison Institute, UT MD Anderson, for support with [study design / data generation / analysis].”
Scientific Leadership
Build the Future of Translational Immunology
The Immunotherapy Platform is recruiting across our teams.
Contact the Immunotherapy Platform
For collaboration inquiries, include study scope, cohort details and timeline in your message.
Address
TMC3 Collaborative Building
255 Helix Park Ave
Houston, TX 77030
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.